CClinicalTrials.gg
RecruitingNCT05851950RUFUSUpdated Oct 23, 2023

RUFUS - Group Rumination-focused CBT for Negative Symptoms

An interventional study of group rumination focused cognitive behavioural therapy and Treatment as usual in Psychotic Disorders, sponsored by Mental Health Services in the Capital Region, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Mental Health Services in the Capital Region, Denmark · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
All
01

Study summary

Abstract - --

Introduction:

Psychosis spectrum disorders are characterized by both positive and negative symptoms, but whereas there is good effect of treatment on positive symptoms, there is still a scarcity of effective interventions aimed at reducing negative symptoms. Rumination has been proposed as an important and fundamental factor in the development and maintenance of symptoms across psychiatric diagnoses, and there is a need to develop effective interventions targeting rumination behaviors and negative symptoms in patients with psychotic disorders. The aim of the current study is to investigate the feasibility and acceptability of group rumination-focused cognitive behavioral therapy (RFCBT) in the treatment of young people with psychosis spectrum disorders as well as investigating potential indications of treatment efficacy.

Methods and analysis: The study is a mixed-method clinical randomized controlled pilot trial with a target sample of 60 patients, who are randomized to either receive 13 weeks of group CFCBT or 13 weeks of treatment as usual (TAU). All patients are examined at the start of the project and at the 13-week follow-up. The researcher will compare changes in outcomes from baseline to posttreatment between group CFCBT and TAU. In addition, qualitative analyzes are carried out to explore feasibility and acceptability and to uncover the patients' experience of receiving the intervention.

02

Conditions studied

  • Psychotic Disorders

Browse trials for

03

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosed with a psychosis spectrum disorder (ICD-10 F2x)
  2. At least 8 months left of their OPUS treatment
  3. The presence of rumination behavior as assessed by a score of minimum 30 on the Perseverative Thinking Questionnaire (PTQ)
  4. Danish-speaking

Exclusion criteria

Exclusion Criteria:

  1. Substance abuse or positive symptoms that make participation in therapy difficult
  2. Severe suicidal thoughts/behavior
  3. Lacks capacity to consent
  4. Mild, moderate, or severe intellectual disability (IQ ˂ 70)
  5. Planned adjustment of antidepressant and/or antipsychotic treatment (noted in the patient's medical record)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    rumination-focused cognitive behavioural group therapy

    1 individual in-take session, 11 sessions of rumination-focused cognitive behavioural group therapy, 1 individual closing session.

    Other: group rumination focused cognitive behavioural therapy

  • Active comparator
    Treatment as usual

    standard OPUS treatment. OPUS treatment is handled by an interdisciplinary OPUS team and consists primarily of medical treatment, psychoeducation, training in symptom management and social skills as well as family discussions. All patients in OPUS have a contact doctor and a contact person who is responsible for coordinating the treatment and collaborating with municipal bodies.

    Other: Treatment as usual

Interventions

  • Othergroup rumination focused cognitive behavioural therapy

    Psychotherapy

  • OtherTreatment as usual

    opus treatment

05

What researchers measure

Primary outcomes

  1. the Brief Negative Symptoms Scale (BNSS)

    Assessment of negative symptoms on a scale from 0-78

    Time frame: up to 20 weeks

Secondary outcomes

  1. Perseverative Thinking Questionnaire (PTQ)

    Measuring frequency of rumination. Resulting in a total score of 0-60.

    Time frame: up to 20 weeks

  2. Ruminative Response Scale (RRS)

    Measuring levels of rumination in relation to depression. Resulting in a total score of 22-88.

    Time frame: up to 20 weeks

  3. Social Functioning Scale (SFS)

    Measuring level of functioning on a scale from of 0-228

    Time frame: up to 20 weeks

  4. Scale for the assessment of positive symptoms (SAPS)

    Measuring presence of positive symptoms on a scale from 0-170

    Time frame: up to 20 weeks

  5. Calgary depression scale (CDS)

    Measuring depressive symptoms on a scale from 0-27

    Time frame: up to 20 weeks

  6. Behavior Rating Inventory of Executive Function (BRIEF)

    Measuring executive functioning on a scale from 75-225

    Time frame: up to 20 weeks

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05851950
Lead sponsor
Mental Health Services in the Capital Region, Denmark
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Aug 1, 2023
Primary completion
Jan 31, 2025 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Oct 23, 2023

Study contacts

Lars Clemmensen
Contact
lars.clemmensen@regionh.dk
23492490
Louise B Glenthøj
principal investigator · Mental health center of Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion